瑞典科学家

阿尔维德·卡尔森（瑞典语：Arvid Carlsson，1923年1月25日-2018年6月29日），瑞典人，出生于瑞典乌普萨拉，毕业于瑞典隆德大学，获得医学博士学位。曾任苏黎士大学兼免疫学研究所所长。 [1] 

2000年荣获诺贝尔生理或医学奖，他是自1982年以来首位获得诺贝尔奖的瑞典科学家。其获奖的原因是他发现了多巴胺这种重要的神经递质。他的研究成果使人们认识到帕金森症和精神分裂症的起因是由于病人的脑部缺乏多巴胺，并据此可以研制出治疗这种疾病的有效药物。

https://baike.baidu.com/item/%E9%98%BF%E5%B0%94%E7%BB%B4%E5%BE%B7%C2%B7%E5%8D%A1%E5%B0%94%E6%A3%AE/1371034?fromModule=lemma_inlink

https://pubmed.ncbi.nlm.nih.gov/12166820/

summary-CarlssonAP-set.txt

Abstract

The effect that research on dopamine and other neutro trasmitters has on disciplines like neurology and psychiatry is described.

Similar articles

• A half-century of neurotransmitter research: impact on neurology and psychiatry (Nobel lecture).

  Carlsson A.Chembiochem. 2001 Aug 3;2(7-8):484-93. doi: 10.1002/1439-7633(20010803)2:7/8<484::AID-CBIC484>3.0.CO;2-5.PMID: 11828480 No abstract available.

• The London Contribution to Neurology and Psychiatry: The second British Symposium on the History of Neurology and Psychiatry.

  Reynolds EH.J Neurol Neurosurg Psychiatry. 2017 Jul;88(7):608-611. doi: 10.1136/jnnp-2016-315514. Epub 2017 Apr 17.PMID: 28416564 No abstract available.

• Epilepsy, psychiatry, and neurology.

  Reynolds EH, Trimble MR.Epilepsia. 2009 Mar;50 Suppl 3:50-5. doi: 10.1111/j.1528-1167.2009.02039.x.PMID: 19298432

• How the conflict between American psychiatry and neurology delayed the appreciation of cognitive dysfunction in multiple sclerosis.

  Butler MA, Corboy JR, Filley CM.Neuropsychol Rev. 2009 Sep;19(3):399-410. doi: 10.1007/s11065-009-9089-y. Epub 2009 Apr 17.PMID: 19373561 Review.

• Classical dopamine agonists.

  Horowski R, Löschmann PA.J Neural Transm (Vienna). 2019 Apr;126(4):449-454. doi: 10.1007/s00702-019-01989-y. Epub 2019 Feb 25.PMID: 30805732 Review.

See all similar articles

Cited by

• The Story of Levodopa: A Long and Arduous Journey.

  Bhattacharyya KB.Ann Indian Acad Neurol. 2022 Jan-Feb;25(1):124-130. doi: 10.4103/aian.aian_474_21. Epub 2022 Feb 22.PMID: 35342258 Free PMC article.

• Indian Rauwolfia research led to the evolution of neuropsychopharmacology & the 2000 Nobel Prize (Part II).

  Tandon PN.Indian J Med Res. 2021 Jul;154(1):169-174. doi: 10.4103/ijmr.ijmr_1674_21.PMID: 34782547 Free PMC article. No abstract available.

• CDNF: An innovative actor in disease-modifying approaches for Parkinson's disease.

  Tenenbaum L.Mol Ther. 2021 Sep 1;29(9):2634-2636. doi: 10.1016/j.ymthe.2021.08.015.PMID: 34473959 Free PMC article. No abstract available.

• Strategies for the Treatment of Parkinson's Disease: Beyond Dopamine.

  Iarkov A, Barreto GE, Grizzell JA, Echeverria V.Front Aging Neurosci. 2020 Jan 31;12:4. doi: 10.3389/fnagi.2020.00004. eCollection 2020.PMID: 32076403 Free PMC article.

• The antipsychotic landscape: dopamine and beyond.

  Morrison PD, Murray RM.Ther Adv Psychopharmacol. 2018 Apr;8(4):127-135. doi: 10.1177/2045125317752915. Epub 2018 Jan 23.PMID: 29607005 Free PMC article. Review.

See all "Cited by" articles

Publication types

• Autobiography

• Biography

• Historical Article

• Lecture

• Portrait

MeSH terms

• Animals

• History, 20th Century

• History, 21st Century

• Humans

• Neurology / history*

• Neurotransmitter Agents / history*

• Neurotransmitter Agents / metabolism

• Psychiatry / history*

• Sweden

Substances

• Neurotransmitter Agents

Personal name as subject

• A Carlsson

Related information

• PubChem Compound

• PubChem Substance

LinkOut - more resources

• Full Text Sources

• Ovid Technologies, Inc.

• Silverchair Information Systems